Article | April 14, 2020

Transparency & Other Takeaways From COVID-19 Clinical Trials

By Darcy Grabenstein

COVID-19 Clinical Trials.jpg

The first U.S. case of the novel coronavirus was confirmed by the Washington State Department of Health on Jan. 21. A Seattle man in his 50s with underlying health conditions died on Feb. 29, marking the first reported death from COVID-19 in the United States.

And on March 16, Jennifer Haller of Seattle was the first person to be injected with the experimental coronavirus vaccine mRNA-1273 in a clinical trial. Haller, 43, works as an operations manager for a technology company. “We all feel so helpless. This is an amazing opportunity for me to do something,” Haller told The Associated Press, adding that her two teenagers “think it’s cool” she’s taking part in the study.

Scientists are calling this first-in-humans study a momentous occasion. Haller’s act of selflessness can be viewed as historic, considering that it took place during Women’s History Month.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Informa Pharma Intelligence